Eliot A Brinton

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, 420 Chipeta Way, Room 1160, Salt Lake City, UT 84108, USA
    Curr Atheroscler Rep 10:25-32. 2008
  2. ncbi Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Am J Cardiovasc Drugs 11:179-87. 2011
  3. ncbi Effects of ethanol intake on lipoproteins and atherosclerosis
    Eliot A Brinton
    Department of Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, Utah 84108, USA
    Curr Opin Lipidol 21:346-51. 2010
  4. ncbi Can menopausal hormone therapy prevent coronary heart disease?
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Trends Endocrinol Metab 19:206-12. 2008
  5. ncbi Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Diabetes Obes Metab 10:1004-11. 2008
  6. ncbi Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease
    Paul N Hopkins
    Cardiovascular Genetics, Department of Internal Medicine, Cardiology Division, University of Utah School of Medicine, 410 Chipeta Way, Salt Lake City, UT 84108, USA
    J Am Coll Cardiol 45:1003-12. 2005
  7. ncbi Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese
    Ted D Adams
    Department of Internal Medicine, Cardiovascular Genetics Division, University of Utah, Salt Lake City, Utah, USA
    Obesity (Silver Spring) 18:121-30. 2010
  8. ncbi Effects of ethanol intake on lipoproteins
    Eliot A Brinton
    Utah Foundation for Biomedical Research, Salt Lake City, UT, USA
    Curr Atheroscler Rep 14:108-14. 2012
  9. ncbi Controversies in dyslipidemias: atheroprevention in diabetes and insulin resistance
    Eliot A Brinton
    Metabolism Section, Cardiology Division, University of Utah, Room 4A100, 30 North 1900 East, Salt Lake City, Utah 84132, USA
    Ann N Y Acad Sci 1055:159-78. 2005
  10. ncbi Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study
    Paul N Hopkins
    Cardiovascular Genetics Research, Department of Internal Medicine, Cardiology Division, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Atherosclerosis 207:559-66. 2009

Detail Information

Publications18

  1. ncbi Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, 420 Chipeta Way, Room 1160, Salt Lake City, UT 84108, USA
    Curr Atheroscler Rep 10:25-32. 2008
    ..This review provides an update on the benefits and risks of fibrate monotherapy and addresses the benefits and risks of adding fibrates to statins...
  2. ncbi Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Am J Cardiovasc Drugs 11:179-87. 2011
    ..In this study, we pooled safety data from available trials of at least 16 weeks' duration to evaluate the impact of flushing on patient adherence to niacin extended-release (NER) therapy...
  3. ncbi Effects of ethanol intake on lipoproteins and atherosclerosis
    Eliot A Brinton
    Department of Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, Utah 84108, USA
    Curr Opin Lipidol 21:346-51. 2010
    ..This article reviews published studies regarding effects of ethanol intake on lipoprotein levels and function as they relate to atherosclerosis, with special emphasis on recent publications in the past 2 years...
  4. ncbi Can menopausal hormone therapy prevent coronary heart disease?
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Trends Endocrinol Metab 19:206-12. 2008
    ..We call for new research on this question, and an evidence-based review of existing recommendations for MHT...
  5. ncbi Novel pathways for glycaemic control in type 2 diabetes: focus on bile acid modulation
    Eliot A Brinton
    Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Diabetes Obes Metab 10:1004-11. 2008
    ..There is renewed interest in the use of bile acid sequestrants in individuals with type 2 diabetes, most of whom would benefit from additional reductions in both LDL-cholesterol and glycaemia...
  6. ncbi Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease
    Paul N Hopkins
    Cardiovascular Genetics, Department of Internal Medicine, Cardiology Division, University of Utah School of Medicine, 410 Chipeta Way, Salt Lake City, UT 84108, USA
    J Am Coll Cardiol 45:1003-12. 2005
    ..This study was designed to explore contributions of plasma total triglycerides (TGs) and type III hyperlipidemia to the risk of premature familial coronary artery disease (CAD)...
  7. ncbi Health outcomes of gastric bypass patients compared to nonsurgical, nonintervened severely obese
    Ted D Adams
    Department of Internal Medicine, Cardiovascular Genetics Division, University of Utah, Salt Lake City, Utah, USA
    Obesity (Silver Spring) 18:121-30. 2010
    ....
  8. ncbi Effects of ethanol intake on lipoproteins
    Eliot A Brinton
    Utah Foundation for Biomedical Research, Salt Lake City, UT, USA
    Curr Atheroscler Rep 14:108-14. 2012
    ..Application of these findings in clinical practice remains problematic, however, due to the lack of randomized, controlled clinical trials of ethanol and due to the potential hazards of ethanol consumption...
  9. ncbi Controversies in dyslipidemias: atheroprevention in diabetes and insulin resistance
    Eliot A Brinton
    Metabolism Section, Cardiology Division, University of Utah, Room 4A100, 30 North 1900 East, Salt Lake City, Utah 84132, USA
    Ann N Y Acad Sci 1055:159-78. 2005
    ..Finally, strategies for maintaining glucose control and the role of inflammation associated with MS/IR and CVD are described...
  10. ncbi Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study
    Paul N Hopkins
    Cardiovascular Genetics Research, Department of Internal Medicine, Cardiology Division, University of Utah School of Medicine, Salt Lake City, UT 84108, USA
    Atherosclerosis 207:559-66. 2009
    ..30 with TG>150mg/dL) indicative of atherogenic remnant accumulation (type III hyperlipidemia). However, virtually no reports are available which examine potential associations between CAD and VLDL-C/TG at the lower end of the spectrum...
  11. ncbi Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence
    S Mitchell Harman
    Kronos Longevity Research Institute, 2222 E Highland, Ste 220, Phoenix, AZ 85016, USA
    Ann N Y Acad Sci 1052:43-56. 2005
    ..It will examine surrogate end points as well as risk factors for atherosclerosis...
  12. ncbi Postmenopausal hormone therapy: new questions and the case for new clinical trials
    JoAnn E Manson
    Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    Menopause 13:139-47. 2006
    ....
  13. ncbi Women, hormones, and clinical trials: a beginning, not an end
    Virginia M Miller
    J Appl Physiol 99:381-3. 2005
  14. ncbi Is the WHI relevant to HRT started in the perimenopause?
    S Mitchell Harman
    Kronos Longevity Research Institute, Phoenix, AZ, USA
    Endocrine 24:195-202. 2004
    ..Furthermore, animal and clinical evidence supports the use of lower doses of estrogen than were employed in the WHI in older/longer postmenopausal women...
  15. ncbi Triglyceride-rich lipoprotein remnant levels and metabolism: time to adopt these orphan risk factors?
    Eliot A Brinton
    J Am Coll Cardiol 43:2233-5. 2004
  16. ncbi Estrogen receptor 1 variants and coronary artery disease: shedding light into a murky pool
    Paul N Hopkins
    JAMA 290:2317-9. 2003
  17. ncbi Lipid abnormalities in the metabolic syndrome
    Eliot A Brinton
    Carl T. Hayden VA Medical Center, Section of Metabolism, Endocrinology, and Nutrition, Department of Internal Medicine, 111 E, 650 East Indian School Road, Phoenix, AZ 85012, USA
    Curr Diab Rep 3:65-72. 2003
    ..These steps are now more feasible and more clearly desirable than ever before. Statins alone greatly reduce atherosclerosis risk, but combination lipid therapy is often required for optimal dyslipidemia management and atheroprevention...
  18. ncbi Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women
    Zoltan Vajo
    Section of Metabolism, Endocrinology and Nutrition, Department of Medicine, Carl T. Hayden VA Medical Center, 111E, 650 E Indian School Road, Phoenix, AZ 85012, USA
    Atherosclerosis 160:495-501. 2002
    ..84, P=0.04). We conclude that intra-abdominal fat may lower HDL levels by increasing the FCR of Lp A-I, suggesting a mechanism by which central adiposity may be proatherogenic...